CO5070586A1 - Combinaciones terapeuticas para la fragilidad musculoesque- letica - Google Patents

Combinaciones terapeuticas para la fragilidad musculoesque- letica

Info

Publication number
CO5070586A1
CO5070586A1 CO99037624A CO99037624A CO5070586A1 CO 5070586 A1 CO5070586 A1 CO 5070586A1 CO 99037624 A CO99037624 A CO 99037624A CO 99037624 A CO99037624 A CO 99037624A CO 5070586 A1 CO5070586 A1 CO 5070586A1
Authority
CO
Colombia
Prior art keywords
fragility
compositions
musculoesque
letica
pyridin
Prior art date
Application number
CO99037624A
Other languages
English (en)
Spanish (es)
Inventor
Hua Zhu Ke
Li Mei
Pan Lydia Codetta
Thompson David Duane
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5070586A1 publication Critical patent/CO5070586A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO99037624A 1998-06-16 1999-06-16 Combinaciones terapeuticas para la fragilidad musculoesque- letica CO5070586A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
CO5070586A1 true CO5070586A1 (es) 2001-08-28

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99037624A CO5070586A1 (es) 1998-06-16 1999-06-16 Combinaciones terapeuticas para la fragilidad musculoesque- letica

Country Status (29)

Country Link
EP (1) EP1085867A1 (zh)
JP (1) JP2002518328A (zh)
KR (1) KR20010052817A (zh)
CN (1) CN1305378A (zh)
AP (1) AP9901581A0 (zh)
AR (1) AR018868A1 (zh)
AU (1) AU3342099A (zh)
BG (1) BG105128A (zh)
BR (1) BR9911357A (zh)
CA (1) CA2335112A1 (zh)
CO (1) CO5070586A1 (zh)
EA (1) EA200001189A1 (zh)
GT (1) GT199900083A (zh)
HR (1) HRP20000857A2 (zh)
HU (1) HUP0102395A2 (zh)
ID (1) ID26726A (zh)
IL (1) IL139587A0 (zh)
IS (1) IS5727A (zh)
MA (1) MA26648A1 (zh)
NO (1) NO20006381D0 (zh)
OA (1) OA11569A (zh)
PA (1) PA8472101A1 (zh)
PE (1) PE20000633A1 (zh)
PL (1) PL345064A1 (zh)
SK (1) SK18902000A3 (zh)
TN (1) TNSN99118A1 (zh)
UY (1) UY25557A1 (zh)
WO (1) WO1999065488A1 (zh)
ZA (1) ZA993973B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
AU2001276608A1 (en) * 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
JP2005515988A (ja) * 2001-11-29 2005-06-02 ジーティーエックス・インコーポレイテッド 骨粗鬆症を引き起こすアンドロゲン欠乏の予防及び治療
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
IL139587A0 (en) 2002-02-10
CA2335112A1 (en) 1999-12-23
PA8472101A1 (es) 2000-09-29
NO20006381L (no) 2000-12-14
JP2002518328A (ja) 2002-06-25
CN1305378A (zh) 2001-07-25
NO20006381D0 (no) 2000-12-14
AR018868A1 (es) 2001-12-12
HRP20000857A2 (en) 2001-10-31
GT199900083A (es) 2000-12-05
MA26648A1 (fr) 2004-12-20
HUP0102395A2 (hu) 2001-11-28
AP9901581A0 (en) 1999-06-30
EA200001189A1 (ru) 2001-06-25
KR20010052817A (ko) 2001-06-25
SK18902000A3 (sk) 2001-12-03
WO1999065488A1 (en) 1999-12-23
TNSN99118A1 (fr) 2005-11-10
ZA993973B (en) 2000-12-15
ID26726A (id) 2001-02-01
UY25557A1 (es) 2001-01-31
PE20000633A1 (es) 2000-07-26
EP1085867A1 (en) 2001-03-28
IS5727A (is) 2000-11-24
PL345064A1 (en) 2001-11-19
BG105128A (en) 2001-11-30
BR9911357A (pt) 2001-03-13
AU3342099A (en) 2000-01-05
OA11569A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
EP1348709A3 (en) Thiazolo (4,5-D) pyrimidine compounds
BG111017A (bg) Нови кристални и аморфна форми на съединението триазоло (4, 5- d)пиримидин
EE04018B1 (et) Tieno[2,3-d]pürimidiindioonid, nende valmistamisemeetod ja neid sisaldavad ravimkoostised
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA199901107A1 (ru) Системы и устройства для лечения переломов костей или больных костей с помощью расширяемых тел (варианты), стерильный набор инструментов для введения в кость (варианты)
WO2003048164A3 (en) Adenosine a2a receptor antagonists
CA2299399A1 (en) Benzenesulfonamide inhibitors of pde-iv and their therapeutic use
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
CO5070586A1 (es) Combinaciones terapeuticas para la fragilidad musculoesque- letica
CA2392168A1 (fr) Analogues de la vitamine d
CO5070587A1 (es) Terapia de combinacion para la fragilidad musculoesqueletica
WO2001080894A3 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
ECSP993021A (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
WO2002076930A3 (en) Substituted diarylureas as stimulators for fas-mediated apoptosis
ECSP993020A (es) Terapia de combinacion para la fragilidad musculoesqueletica
MXPA03003198A (es) 3,4-dihidro-pirido [1,2-a]pirimidinas sustituidas.
Joseph DEVELOPING WORLD
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน
IT1262567B (it) Pirrolidin-2-oni,loro preparazione,composizioni farmaceutiche che li contengono e loro uso in terapia.
UA40196A (uk) Спосіб хірургічного лікування переломовивиху проксимального кінця плечової кістки
ITMI931616A0 (it) Chiodo endomidollare per uso in osteosintesi per il trattamento chirurgico delle fratture diafisometafisarie di femore e di tibia.
AR003117A1 (es) El uso de derivado de aminotetralina para la preparacion de composiciones farmaceuticas para la terapia de enfermedades cardiovasculares y dichascomposiciones farmaceuticas.